KRAS and non-small cell lung carcinoma: The TAILOR trial data shed light on the possibility that there was a small negative prognostic effect of KRAS mutations in advanced NSCLC patients treated with a platinum-based doublet when EGFR-mutant patients were excluded from the analysis [5].